2020
DOI: 10.1016/j.mjafi.2020.08.004
|View full text |Cite
|
Sign up to set email alerts
|

Favipiravir: A new and emerging antiviral option in COVID-19

Abstract: With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
294
1
10

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 340 publications
(308 citation statements)
references
References 18 publications
3
294
1
10
Order By: Relevance
“…Due to its successful antiviral potency, various researchers have made considerable efforts to modify, optimize, and develop facile and cost effective routes to the synthesis of favipiravir [12][13][14][15]. Sequel to the recent outbreak of the novel Coronavirus disease 2019 (COVID- 19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the world, favipiravir is investigated as one of the potential drugs for the experimental treatment of the novel coronavirus disease [16][17][18][19][20][21][22][23][24][25][26].…”
Section: Introductionmentioning
confidence: 99%
“…Due to its successful antiviral potency, various researchers have made considerable efforts to modify, optimize, and develop facile and cost effective routes to the synthesis of favipiravir [12][13][14][15]. Sequel to the recent outbreak of the novel Coronavirus disease 2019 (COVID- 19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the world, favipiravir is investigated as one of the potential drugs for the experimental treatment of the novel coronavirus disease [16][17][18][19][20][21][22][23][24][25][26].…”
Section: Introductionmentioning
confidence: 99%
“…Reflecting heightened interest in COVID-19, the front-page of DrugCentral 2021 now includes a list of drugs that are ‘in the news’ (Figure 3 ). The current list includes favipiravir, which is not available in the US, but approved as Avigan in Japan and Russia and emergency approved in Italy ( 48 ) and remdesivir, which was granted emergency authorization in Japan and was FDA-approved as Veklury ( https://bit.ly/33zA8Su ), among other drugs.…”
Section: New Data and Functionalitymentioning
confidence: 99%
“…Favipiravir was used to treat mild and moderate COVID-19 in several countries based on emergency approval. Clinical studies to assess its efficacy in the treatment of COVID-19 alone or in combination with other drugs are ongoing [121]. An overview of remdesivir and favipiravir within the catalytic site of the RdRp of SARS-CoV-2 is depicted in Figure 11.…”
Section: Small Molecule Inhibitors Of Coronaviruses' Rdrpmentioning
confidence: 99%